• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RYTM

    Rhythm Pharmaceuticals Inc.

    Subscribe to $RYTM
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: rhythmtx.com

    Peers

    $XFOR

    Recent Analyst Ratings for Rhythm Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    4/7/2025$63.00Neutral → Buy
    BofA Securities
    3/5/2025$78.00Buy
    Stifel
    1/2/2025$80.00Buy
    Jefferies
    12/20/2024$76.00Outperform
    Oppenheimer
    10/21/2024$70.00Buy
    Guggenheim
    9/18/2024$64.00Buy
    H.C. Wainwright
    9/17/2024$64.00Mkt Outperform
    JMP Securities
    5/8/2024$49.00 → $42.00Buy → Neutral
    BofA Securities
    12/19/2023$29.00 → $55.00Equal-Weight → Overweight
    Morgan Stanley
    8/1/2023$22.00 → $27.00Neutral → Buy
    BofA Securities
    See more ratings